MLZ ist eine Kooperation aus:

Technische Universität München> Technische Universität MünchenHelmholtz-Zentrum Hereon> Helmholtz-Zentrum Hereon
Forschungszentrum Jülich> Forschungszentrum Jülich

MLZ ist Mitglied in:

LENS> LENSERF-AISBL> ERF-AISBL

MLZ in den sozialen Medien:

Logo

MLZ

Lichtenbergstr.1
85748 Garching

» zurück

When Physics Meets Medicine

Targeted Radionuclide Therapy of Cancer for Precision Oncology

Precision medicine is defined as treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Inherent in this definition is the goal of improving clinical outcomes for individual patients and minimizing unnecessary side effects for those less likely to have a response to a particular treatment.

Over the past decade, the use of Gallium-68 labeled somatostatin receptor (SSTR) PET/CT imaging followed by Lutetium-177 labeled SSTR-agonist (DOTATATE or DOTATOC) for peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management of neuroendocrine neoplasms. Highly promising advances are being made in the management of advanced stage, progressive treatment refractory prostate cancer by applying the principle of theranostics (integration of diagnostics and therapeutics in the individualized management of disease). Clinical studies demonstrated that Ga-68 PSMA PET/CT for molecular imaging of biochemical recurrence and restaging of prostate cancer is being widely accepted as a superior imaging modality – followed by the unique possibility of effective treatment of the disease with the beta-particle emitting Lu-177 PSMA and/or the alpha-particle emitting Actinium-225 PSMA.

Rapid advances are being made in the development of several radiometals potentially useful for theranostics. Matched pairs of radionuclides are being developed from the same element with comparable half-lives, to allow preparation of chemically identical radiopharmaceuticals for diagnostic and therapeutic purposes. Examples of such theranostic radionuclide pairs currently under investigation are matched pairs of yttrium (86Y/90Y), copper (64Cu/67Cu), scandium (43/44Sc/47Sc), terbium (155/152Tb/149/161Tb) and lead (203Pb/212Pb).

Student event: Meet the speaker

We invite you to a student-only discussion-round with Prof. Dr. Richard Baum before his Munich Physics Colloquium talk.

Be curious and feel free to ask any question.

Monday, 11 June 2018, 16:00 h
Seminar room PH 3076 (upper floor), Physik-Department der TUM, James-Franck-Straße 1, Garching

Seminar

Datum11.06.2018
Uhrzeit17:15 - 18:30 Uhr
OrtGarching
RaumHS 2 (Physik-Department)
SprecherProf. Dr. Richard P. Baum, Zentralklinik Bad Berka
Veranstalter

LMU / TUM


Kontakt

URL

https://www.physik.uni-muenchen.de

MLZ ist eine Kooperation aus:

Technische Universität München> Technische Universität MünchenHelmholtz-Zentrum Hereon> Helmholtz-Zentrum Hereon
Forschungszentrum Jülich> Forschungszentrum Jülich

MLZ ist Mitglied in:

LENS> LENSERF-AISBL> ERF-AISBL

MLZ in den sozialen Medien: